Hospital pharmacist’s roles and responsibilities with CAR-T medicines
The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain’s hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist’s role with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11333.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846146014440849408 |
|---|---|
| author | María Estela Moreno-Martínez Joan Vinent-Genestar Carmen Muñoz-Sánchez María Josep Carreras-Soler |
| author_facet | María Estela Moreno-Martínez Joan Vinent-Genestar Carmen Muñoz-Sánchez María Josep Carreras-Soler |
| author_sort | María Estela Moreno-Martínez |
| collection | DOAJ |
| description | The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain’s hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist’s role within the ultidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients treated with this type of therapy, and emphasizing on the management of its main adverse effects. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the rest of the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity –and even improving previously established basic processes–. |
| format | Article |
| id | doaj-art-3a0354875fcd4734b5f029d4570e699e |
| institution | Kabale University |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-3a0354875fcd4734b5f029d4570e699e2024-12-02T04:55:26ZengElsevierFarmacia Hospitalaria1130-63432171-86952020-01-01441263110.7399/fh.11333Hospital pharmacist’s roles and responsibilities with CAR-T medicinesMaría Estela Moreno-Martínez0Joan Vinent-Genestar1Carmen Muñoz-Sánchez2María Josep Carreras-Soler3Pharmacy Service, Santa Creu i Sant Pau Hospital, Barcelona. Spain.Pharmacy Service, Sant Joan de Déu Hospital, Esplugues de Llobregat. Spain.Pharmacy Service, Catalan Institute of Oncology, Hospitalet de Llobregat. Spain.Pharmacy Service, Vall d’Hebron University Hospital, Barcelona. Spain.The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain’s hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist’s role within the ultidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients treated with this type of therapy, and emphasizing on the management of its main adverse effects. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the rest of the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity –and even improving previously established basic processes–.http://www.aulamedica.es/fh/pdf/11333.pdft-cell chimeric antigen receptorcytokine release syndromecar-t-related encephalopathy syndromepharmaceutical care |
| spellingShingle | María Estela Moreno-Martínez Joan Vinent-Genestar Carmen Muñoz-Sánchez María Josep Carreras-Soler Hospital pharmacist’s roles and responsibilities with CAR-T medicines Farmacia Hospitalaria t-cell chimeric antigen receptor cytokine release syndrome car-t-related encephalopathy syndrome pharmaceutical care |
| title | Hospital pharmacist’s roles and responsibilities with CAR-T medicines |
| title_full | Hospital pharmacist’s roles and responsibilities with CAR-T medicines |
| title_fullStr | Hospital pharmacist’s roles and responsibilities with CAR-T medicines |
| title_full_unstemmed | Hospital pharmacist’s roles and responsibilities with CAR-T medicines |
| title_short | Hospital pharmacist’s roles and responsibilities with CAR-T medicines |
| title_sort | hospital pharmacist s roles and responsibilities with car t medicines |
| topic | t-cell chimeric antigen receptor cytokine release syndrome car-t-related encephalopathy syndrome pharmaceutical care |
| url | http://www.aulamedica.es/fh/pdf/11333.pdf |
| work_keys_str_mv | AT mariaestelamorenomartinez hospitalpharmacistsrolesandresponsibilitieswithcartmedicines AT joanvinentgenestar hospitalpharmacistsrolesandresponsibilitieswithcartmedicines AT carmenmunozsanchez hospitalpharmacistsrolesandresponsibilitieswithcartmedicines AT mariajosepcarrerassoler hospitalpharmacistsrolesandresponsibilitieswithcartmedicines |